AIM ImmunoTech Inc. (NYSE:AIM)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $1.46, but opened at $1.29. AIM ImmunoTech shares last traded at $1.33, with a volume of 68,144 shares.
AIM has been the subject of a number of analyst reports. Maxim Group upgraded shares of AIM ImmunoTech from a “hold” rating to a “buy” rating in a report on Thursday, October 10th. TD Securities upgraded shares of AIM ImmunoTech to a “buy” rating and lifted their price objective for the company from $4.25 to $4.50 in a report on Tuesday, January 14th.
The firm has a market cap of $9.01 million, a PE ratio of -0.19 and a beta of 0.90. The company’s fifty day moving average price is $0.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.01 and a quick ratio of 3.01.
A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 185,171 shares of the company’s stock, valued at approximately $141,000. Sabby Management LLC owned about 2.24% of AIM ImmunoTech at the end of the most recent reporting period. Institutional investors and hedge funds own 15.41% of the company’s stock.
About AIM ImmunoTech (NYSE:AIM)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading: Which market index is the best?
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.